Pharsight

Qbrexza generic

Qbrexza is a topical treatment owned by Journey. It contains the active ingredient, glycopyrronium tosylate. The drug was first authorized for marketing on 28 June, 2018. Qbrexza, especially known for its use in treating primary axillary hyperhidrosis, can be utilized by both adults and pediatric patients who are 9 years or older.

When will Qbrexza generic be available?

Qbrexza has a total of 8 patents, none of which have expired yet. The potential release date for a Qbrexza generic version is after 28 February, 2033. This is the expiration date of the last patent owned by the drug.

Qbrexza uses

Qbrexza is mainly used as a topical treatment for primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Its active ingredient, glycopyrronium tosylate, is known for its effectiveness in managing the excessive sweating associated with this condition.

Qbrexza patent expiration

Qbrexza, owned by Journey, holds a total of 8 patents related to its formulation and usage. None of these patents have expired, with the latest patent expiring on the 28th of February, 2033. This makes it the likely earliest release date for the Qbrexza generic version. Below are the details of the patent:

Qbrexza dosage

Want to ask something?